Upgrade to SI Premium - Free Trial

Gilead Sciences (GILD) Reiterated at Overweight by Cantor Fitzgerald

June 9, 2026 6:54 AM
Cantor Fitzgerald analyst Carter Gould reiterated an Overweight rating and $155.00 price target on Gilead Sciences (NASDAQ: GILD).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments